AJP - Heart BIOPAC complete lab solutions
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Heart Circ Physiol 284: H1904-H1908, 2003. First published January 30, 2003; doi:10.1152/ajpheart.01150.2002
0363-6135/03 $5.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
284/6/H1904    most recent
01150.2002v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (13)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schanstra, J. P.
Right arrow Articles by Bascands, J.-L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schanstra, J. P.
Right arrow Articles by Bascands, J.-L.
Vol. 284, Issue 6, H1904-H1908, June 2003

SPECIAL TOPICS
Regulation of Cardiovascular Signaling by Kinins and Products of Similar Converting Enzyme Systems
Decreased renal NO excretion and reduced glomerular tuft area in mice lacking the bradykinin B2 receptor

Joost P. Schanstra1, Johan Duchene1, Françoise Praddaude1, Patrick Bruneval2, Ivan Tack1, Jacques Chevalier2, Jean-Pierre Girolami1, and Jean-Loup Bascands1

1 Institut National de la Santé et de la Recherche Médicale U388, Institut Louis Bugnard, Centre Hospitalier Universitaire Rangueil, 31052 Toulouse; 2 Institut National de la Santé et de la Recherche Médicale U430, Hôpital Broussais, 75674 Paris Cedex 14, France


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Bradykinin B2 receptor knockout mice (B2-/-) have been useful to study the role of bradykinin under pathological conditions. With the use of these mice, it was shown that bradykinin plays an important role in angiogenesis, heart failure, salt-induced hypertension, and kidney fibrosis. Data on the role of the bradykinin B2 receptor under physiological conditions using these mice are controversial and scarce, because these mice have no typical phenotype. For this reason, we have studied, under physiological conditions, renal hemodynamics as well as a number of morphometric glomerular parameters of B2-/- mice on a homogenized genetic background and on mice bred in a pathogen-free environment. Backcrossed B2-/- mice had normal blood pressure and normal apparent renal hemodynamics and morphology. However, reduced renal nitrite excretion and glomerular cGMP content were found, which was associated with a reduced glomerular capillary surface area. These differences had, however, no detectable effects on renal hemodynamics. These differences between B2-/- and wild-type mice might become important under pathological conditions as shown by a number of studies using these bradykinin B2 receptor knockout mice.

kidney; hemodynamics; nitric oxide; backcross; genetic background


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

THE DEVELOPMENT of genetically engineered mice lacking the bradykinin B2 receptor (B2-/-) (4) has allowed to better define the physio(patho)logical actions of bradykinin. The nonapeptide bradykinin is generated by the proteolytic action of the serine protease kallikrein from kininogen (3). Pharmacological studies have shown that kinins exert their biological effects through the activation of two seven-transmembrane domain G protein-coupled receptors named B1 and B2 receptor (20). The natural agonist of the B2 receptor is bradykinin and its degradation by a carboxypeptidase produces the B1 receptor agonist [des-Arg9]bradykinin (20). The B1 receptor is weakly detectable under physiological conditions but is strongly expressed in pathological states (16). The B2 receptor, which is constitutively expressed, mediates most of the known effects of bradykinin.

It is now generally admitted that bradykinin plays an essential role in renal homeostasis (23, 24). In the kidney, the most pronounced effects of bradykinin are the reduction of vascular resistance (RVR), the increase in renal blood flow (RBF) with no change in the glomerular filtration rate (GFR), and augmentation of natriuresis and diuresis (2, 13, 27). These natriuretic and diuretic effects of bradykinin are due, at least in part, to the activation of B2 receptors in the medullary thick ascending limb of the loop of Henle (9).

B2-/- mice do not display a specific phenotype. For example, because bradykinin is a well-known vasodilator peptide, a higher blood pressure (BP) under basal conditions was expected in B2-/- mice. However, the majority of the papers studied thus far showed no difference in BP between B2-/- and wild-type mice (1, 6, 18) except for one study, which reported a higher BP in the B2-/- mice (15).

When fed a high-salt diet, B2-/- mice developed salt-sensitive hypertension, which was absent in wild-type mice. This salt-sensitive hypertension was associated with a reduced RBF and an increased RVR (1). This salt-sensitive hypertension was confirmed in another study using B2-/- mice (15); however, renal function was not studied. In contrast, a more recent study showed that increasing dietary salt intake did not modify BP and RBF in B2-/- mice, whereas the diet increased RBF in wild-type mice (18).

As recently reviewed, it is now well admitted that differences in genetic background of genetically modified mice leads to divergent results between different laboratories (25). The observed differences for B2-/- mice might thus originate in differences in the genetic background of the used mice strains and therefore might not be due to the absence of the B2 receptor. The current study was setup to investigate, under physiological conditions, renal hemodynamics as well as some morphometric glomerular parameters of B2-/- mice on a homogenized genetic background and on mice bred in a pathogen-free environment.


    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Animals. B2-/- mice were generously provided by Drs. F. Hess and T. MacNeil (Merck; Rahway, NJ) (4). B2-/- mice were originally on a mixed genetic background (J129sv × C57Bl/6J). B2-/- mice were backcrossed for 10 generations against a C57Bl/6J background, and the homogeneity of the background was verified by microsatellite analysis (Nucleis; Angers, France; Table 1). Furthermore, mice were housed in a pathogen-free environment.

                              
View this table:
[in this window]
[in a new window]
 
Table 1.   Results of microsatellite sequence analysis

Experimental protocols. Male mice at the age of 8 wk were used in these experiments, 10 mice in each group. Mice were maintained on a standard mouse chow and tap water. For the metabolic study, mice were housed individually in metabolic cages (Marty Technologie) in a temperature (20°C) and photoperiod (7 AM to 7 PM)-controlled room. They were allowed free access to standard chow and water. Food and water consumption and urine secretion were determined gravimetrically once a day for each mouse during 3 days. Nitrite concentrations in urine samples were determined colorimetrically (Roche Molecular Biochemicals; Meylan, France). Na+ and K+ concentrations were determined by flame photometry. In vivo renal hemodynamic measurements on mice were performed as previously described for rats with minor modifications (21). Arterial blood samples were taken at the end of the urine collection period. Renal hemodynamic parameters were calculated as described (19). Measurement of blood pressure was performed in anesthetized mice by the tail-cuff plethysmography method as described (17). All experiments reported were conducted as stated in the National Institutes of Health Guide For The Care And Use Of Laboratory Animals (Institute of Laboratory Animal Resources, National Academy Press, Washington DC, 1996) and were approved by a local animal care and use committee.

Histological and morphometric analysis. For histological studies, kidneys were fixed in alcoholic Bouin's solution, embedded in paraffin, sectioned at 4 µm, and stained with hematoxylin according to routine histological staining (22). Morphometric measurements of the different glomerular and capillary surfaces were performed by using an automated image-analyzing system as previously described in detail (10).

Isolation of glomeruli and cGMP measurements. Glomeruli were obtained as described previously (14). cGMP content was measured as previously described (28) using an EIA-kit from Cayman Chemical (Ann Arbor, MI).

Statistical analysis. Values are expressed as means ± SD. Data were compared using SPSS software (SPSS Science; Chicago, IL). ANOVA with post hoc Tukey's alpha -test was performed for comparison between groups. P values <0.05 were considered as significant.


    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

B2-/- mice are genetically comparable to C57Bl/6J mice. After homogenization of the genetic background of B2-/- mice by 10 backcrosses, microsatellite analysis showed that B2-/- mice are now genetically comparable to C57BL/6J mice (Table 1). C57BL/6J mice were used as control mice in all experiments.

B2-/- mice display normal renal and systemic hemodynamic parameters. It is well known that bradykinin, via the B2 receptor, induces vasodilatation and is natriuretic and diuretic. However, no difference was observed in BP, heart rate (HR), renal plasma flow (RPF), GFR, and RVR between wild-type and B2-/- mice (Fig. 1). A 3-day metabolic study (Table 2) showed that body weight, food and water intake, urinary flow, urine sodium and potassium excretion, as well as osmolality, did not differ significantly between both groups. However, nitrite excretion was significantly reduced in B2-/- mice (0.13 ± 0.01 µmol/24 h) compared with wild-type mice (0.79 ± 0.12 µmol/24 h, P < 0.01).


View larger version (28K):
[in this window]
[in a new window]
 
Fig. 1.   Tail-cuff blood pressure (BP), heart rate (HR), renal plasma flow (RPF), glomerular filtration rate (GFR), and renal vascular resistance (RVR) in male bradykinin B2 receptor knock-out (B2-/-) and wild-type (WT) mice. n = 10 mice in each group. Values are presented as means ± SD.


                              
View this table:
[in this window]
[in a new window]
 
Table 2.   Three-day metabolic study

B2-/- mice have a decreased glomerular capillary surface area. No difference in the histological structure of the kidney was observed between B2-/- and wild-type mice. Wild-type and B2-/- mice had the same number of glomeruli (respectively 88.8 ± 6 and 88.3 ± 5 per kidney section, n = 10). However, morphometrical analysis of at least 40 glomeruli per kidney section showed that the B2-/- mice have a reduced glomerular tuft area, which is caused by a decreased capillary surface area of 25 ± 8% (Fig. 2). In contrast, the glomerular surface area was not different between both mice strains.


View larger version (99K):
[in this window]
[in a new window]
 
Fig. 2.   Morphometric analysis of different glomerular domains. A: whole glomerular surface (glomerular), glomerular tuft area, and glomerular capillary surface. n = 10 mice in each group. Values are presented as means ± SD. Forty glomeruli were analyzed per kidney section. *P < 0.01 compared with WT value. B: representative glomerular section showing glomerular capillary network and mesangium of wild-type mice. C: representative glomerular section showing glomerular capillary network and mesangium of B2-/- mice. Capillary lumens are larger in wild-type than those in B2-/- mice.

Glomeruli of B2-/- mice have reduced cGMP levels. As shown by the metabolic study, B2-/- mice had a decreased urinary nitrite excretion, which was associated with a decrease in the glomerular capillary surface area, suggesting a preconstricted mesangium due to decreased vasodilatory factor levels. To further explore this hypothesis, we studied basal and the stimulated production of cGMP in isolated mouse glomeruli. As shown in Fig. 3, a significant (50%) decrease in basal cGMP levels was observed in isolated glomeruli of B2-/- mice compared with wild-type mice. When the glomeruli were stimulated with calcium ionophore A23187, an increase in the cGMP content was observed in both wild-type and B2-/- mice. The ionophore-induced cGMP production was significantly higher in wild-type than in B2-/- mice, although the relative increase in cGMP levels between both mouse strains was comparable.


View larger version (16K):
[in this window]
[in a new window]
 
Fig. 3.   Variations in cGMP content of isolated glomeruli from B2-/- and WT mice under basal conditions (control) and stimulated with the calcium ionophore (A23187). Values are presented as means ± SD of 6 distinct experiments. *P < 0.01 compared with WT value.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

The main goal of this study was to determine, on a homogenized genetic background, renal function and morphology of B2-/- and wild-type mice. Consistent with previous reports (1, 6, 18, 29), we found that under physiological conditions B2-/- mice have normal BP and a normal HR. We thus confirm on a genetically controlled background that under physiological conditions, i.e normal sodium diet, the bradykinin B2 receptor plays a minor role in BP regulation. It is, however, difficult to exclude compensatory mechanisms for the absence of the B2 receptor in these mice. However, on a mixed J129sv × C57Bl/6J genetic background, there was no modification of the renin-angiotensin system in B2-/- mice (15).

To obtain more insight in the in vivo renal function and morphology of B2-/- mice, we performed a metabolic study, determined several renal parameters, performed classical histomorphology, and determined a number of glomerular morphological parameters. As previously reported (1, 7, 18), GFR, RPF, and RVR were not different between both strains. Furthermore, the majority of the urinary parameters was comparable between wild-type and B2-/- mice. However, a significantly lower urinary NO2 excretion was observed in B2-/- mice. Classic kidney histomorphological analysis did not show any difference between B2-/- and wild-type mice. But glomerular morphology analysis of a large number of glomeruli showed a significant decrease in the size of the glomerular tuft area, which could be attributed to a decreased capillary surface of ~20%. Interestingly and consistent with our data, a reduction of the glomerular tuft area was found in mice having three copies of the angiotensin I-converting enzyme (ACE) (11). Indeed, because ACE has a higher affinity for bradykinin than for angiotensin I (12), overexpression of ACE could result in a decreased bradykinin concentration and, as a consequence, mimic the reduced glomerular tuft area observed in B2-/- animals. The decreased urinary nitrite concentration in B2-/- mice suggests impaired nitric oxide (NO) release in this strain, which could account for the observed reduced glomerular tuft area. In the B2-/- mice, it is possible that bradykinin, normally generating NO, is no longer able to counteract the action of endogenous vasoconstrictors, such as angiotensin II.

To verify that this decrease in the glomerular tuft area might be due to an impaired release of NO and not to anatomic abnormalities, we have measured the cGMP content in isolated glomeruli under basal and stimulated conditions. We found a net 50% decrease in basal cGMP content in the glomeruli of B2-/- mice compared with wild-type mice. Moreover, stimulation of the isolated glomeruli with the calcium ionophore A23187 produced a higher increase in cGMP content in wild-type glomeruli than in glomeruli of B2-/- mice, indicating a functional but reduced NO-cGMP pathway in the B2-/- animals. This lower cGMP production observed in isolated glomeruli under basal conditions can explain the decrease in capillary tuft area in the B2-/- mice, but it is without consequences on the renal function at least under physiological conditions. Interestingly, when stimulated by the calcium-ionophore, the cGMP content is still inferior in B2-/- compared with wild-type mice. These data reinforce the hypothesis suggested by others that impairment in the NO-cGMP pathway is an important reason why B2-/- mice are less resistant to pathological insults. Indeed, indirect evidence has suggested that the B2-/- mice have an impaired ability to release NO. Alfie et al. (1) also proposed an impaired ability to release NO to explain the shift to the right of the mean arterial pressure curve in response to acetylcholine in B2-/- mice compared with control mice. Furthermore, based on data obtained after NO synthase blockade by NG-nitro-L-arginine methyl ester, this impaired ability to release NO could also explain the enhanced susceptibility to angiotensin II-induced hypertension (7). Reduced NO release could also explain the increased RVR recently reported in B2-/- mice (29). We were, however, not able to detect any significant variation in the RVR. These authors, who have also homogenized the genetic background of their animals, have used female mice, whereas we have used male mice. Moreover their animals were 12 wk older than the animals that we used. It is thus possible that B2-/- mice develop, with age, an increased RVR, which is, at the kidney level, without functional consequence at 2 mo but becomes detectable at 5 mo. This progressive increase in RVR could be explained by the absence of the physiological tonic vasodilatory effect of bradykinin in these mice mainly due to this impaired NO-cGMP pathway. Consistent with the above data, it has been recently reported that transgenic mice overexpressing the B2 receptor have increased renal hemodynamic parameters (increase in RBF and GFR), which was associated to an increased urinary NO2 and NO3 excretion (30).

In summary, we have shown that in our B2-/- mice, under physiological conditions, the B2 bradykinin receptor was not necessary to maintain normal blood pressure, renal hemodynamics, and salt balance. Nevertheless, the B2-/- mice, compared with wild-type animals on the same genetic background, exhibit significant spontaneous differences in terms of reduced glomerular tuft area associated with a lower urinary NO2 excretion.

Apparently, thus without significant consequence under physiological conditions, the bradykinin B2 receptor has been shown, using B2-/- mice, to play an important role under different pathological conditions, including hypertension, heart failure, angiogenesis, and kidney fibrosis (5, 8, 22, 26, 31, 32).


    ACKNOWLEDGEMENTS

We are grateful to M. J. Fouque and M. T. Garelli for technical assistance.


    FOOTNOTES

This work was supported by the Institut National de la Santé et de la Recherchè Médicale. Johan Duchene is a recipient of a fellowship from the Ministère de la Recherche et de la Technologie.

Address for reprint requests and other correspondence: J. L. Bascands, INSERM U388, Institut Louis Bugnard, CHU Rangueil, 31052 Toulouse, France (E-mail: bascalou{at}toulouse.inserm.fr).

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

First published January 30, 2003;10.1152/ajpheart.01150.2002

Received 30 December 2002; accepted in final form 24 January 2003.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

1.   Alfie, ME, Sigmon DH, Pomposiello SI, and Carretero OA. Effect of high salt intake in mutant mice lacking bradykinin-B2 receptors. Hypertension 29: 483-487, 1997[Abstract/Free Full Text].

2.   Beierwaltes, WH, Carretero OA, and Scicli AG. Renal hemodynamics in response to a kinin analogue antagonist. Am J Physiol Renal Fluid Electrolyte Physiol 255: F408-F414, 1988[Abstract/Free Full Text].

3.   Bhoola, KD, Figueroa CD, and Worthy K. Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev 44: 1-80, 1992[Web of Science][Medline].

4.   Borkowski, JA, Ransom RW, Seabrook GR, Trumbauer M, Chen H, Hill RG, Strader CD, and Hess JF. Targeted disruption of a B2 bradykinin receptor gene in mice eliminates bradykinin action in smooth muscle and neurons. J Biol Chem 270: 13706-13710, 1995[Abstract/Free Full Text].

5.   Brochu, I, Labonte J, Bkaily G, and D'Orleans-Juste P. Role of endothelin receptors in the hypertensive state of kinin B(2) knockout mice subjected to a high-salt diet. Clin Sci (Lond) 103, Suppl 48: 380S-384S, 2002[Medline].

6.   Cervenka, L, Harrison-Bernard LM, Dipp S, Primrose G, Imig JD, and El-Dahr SS. Early onset of salt-sensitive hypertension in bradykinin B(2) receptor null mice. Hypertension 34: 176-180, 1999[Abstract/Free Full Text].

7.   Cervenka, L, Maly J, Karasova L, Simova M, Vitko S, Hellerova S, Heller J, and El-Dahr SS. Angiotensin II-induced hypertension in bradykinin B2 receptor knockout mice. Hypertension 37: 967-973, 2001[Abstract/Free Full Text].

8.   Emanueli, C, Bonaria Salis M, Figueroa C, Chao J, Chao L, Gaspa L, Capogrossi MC, and Madeddu P. Participation of kinins in the captopril-induced inhibition of intimal hyperplasia caused by interruption of carotid blood flow in the mouse. Br J Pharmacol 130: 1076-1082, 2000[Web of Science][Medline].

9.   Grider, J, Falcone J, Kilpatrick E, Ott C, and Jackson B. Effect of bradykinin on NaCl transport in the medullary thick ascending limb of the rat. Eur J Pharmacol 287: 101-104, 1995[Web of Science][Medline].

10.   Heudes, D, Michel O, Chevalier J, Scalbert E, Ezan E, Bariety J, Zimmerman A, and Corman B. Effect of chronic ANG I-converting enzyme inhibition on aging processes. I. Kidney structure and function. Am J Physiol Regul Integr Comp Physiol 266: R1038-R1051, 1994[Abstract/Free Full Text].

11.   Huang, W, Gallois Y, Bouby N, Bruneval P, Heudes D, Belair MF, Krege JH, Meneton P, Marre M, Smithies O, and Alhenc-Gelas F. Genetically increased angiotensin I-converting enzyme level and renal complications in the diabetic mouse. Proc Natl Acad Sci USA 98: 13330-13334, 2001[Abstract/Free Full Text].

12.   Jaspard, E, Wei L, and Alhenc-Gelas F. Differences in the properties and enzymatic specificities of the two active sites of angiotensin I-converting enzyme (kininase II). Studies with bradykinin and other natural peptides. J Biol Chem 268: 9496-9503, 1993[Abstract/Free Full Text].

13.   Lortie, M, Regoli D, Rhaleb NE, and Plante GE. The role of B1- and B2-kinin receptors in the renal tubular and hemodynamic response to bradykinin. Am J Physiol Regul Integr Comp Physiol 262: R72-R76, 1992[Abstract/Free Full Text].

14.   MacKay, K, Striker LJ, Elliot S, Pinkert CA, Brinster RL, and Striker GE. Glomerular epithelial, mesangial, and endothelial cell lines from transgenic mice. Kidney Int 33: 677-684, 1988[Web of Science][Medline].

15.   Madeddu, P, Varoni MV, Palomba D, Emanueli C, Demontis MP, Glorioso N, Dessi-Fulgheri P, Sarzani R, and Anania V. Cardiovascular phenotype of a mouse strain with disruption of bradykinin B2 receptor gene. Circulation 96: 3570-3578, 1997[Abstract/Free Full Text].

16.   Marceau, F, Hess JF, and Bachvarov DR. The B1 receptors for kinins. Pharmacol Rev 50: 357-386, 1998[Abstract/Free Full Text].

17.   Marin-Castano, ME, Schanstra JP, Neau E, Praddaude F, Pecher C, Ader JL, Girolami JP, and Bascands JL. Induction of functional bradykinin B(1)-receptors in normotensive rats and mice under chronic angiotensin-converting enzyme inhibitor treatment. Circulation 105: 627-632, 2002[Abstract/Free Full Text].

18.   Milia, AF, Gross V, Plehm R, De Silva JA, Jr, Bader M, and Luft FC. Normal blood pressure and renal function in mice lacking the bradykinin B(2) receptor. Hypertension 37: 1473-1479, 2001[Abstract/Free Full Text].

19.   Praddaude, F, Tack I, Emond C, Bascands JL, Girolami JP, Tran-Van T, Regoli D, and Ader JL. In vivo and in vitro homologous desensitization of rat glomerular bradykinin B2 receptors. Eur J Pharmacol 294: 173-182, 1995[Web of Science][Medline].

20.   Regoli, D, and Barabe J. Pharmacology of bradykinin and related kinins. Pharmacol Rev 32: 1-46, 1980[Web of Science][Medline].

21.   Schanstra, JP, Marin-Castano ME, Praddaude F, Tack I, Ader JL, Girolami JP, and Bascands JL. Bradykinin B(1) receptor-mediated changes in renal hemodynamics during endotoxin-induced inflammation. J Am Soc Nephrol 11: 1208-1215, 2000[Abstract/Free Full Text].

22.   Schanstra, JP, Neau E, Drogoz P, Arevalo Gomez MA, Lopez Novoa JM, Calise D, Pecher C, Bader M, Girolami JP, and Bascands JL. In vivo bradykinin B2 receptor activation reduces renal fibrosis. J Clin Invest 110: 371-379, 2002[Web of Science][Medline].

23.   Scicli, AG, and Carretero OA. Renal kallikrein-kinin system. Kidney Int 29: 120-130, 1986[Web of Science][Medline].

24.   Margolius, HS. Kallikreins and kinins. Some unanswered questions about system characteristics and roles in human disease. Hypertension 26: 221-229, 1995[Abstract/Free Full Text].

25.   Sigmund, CD. Viewpoint: are studies in genetically altered mice out of control? Arterioscler Thromb Vasc Biol 20: 1425-1429, 2000[Abstract/Free Full Text].

26.   Silvestre, JS, Bergaya S, Tamarat R, Duriez M, Boulanger CM, and Levy BI. Proangiogenic effect of angiotensin-converting enzyme inhibition is mediated by the bradykinin B(2) receptor pathway. Circ Res 89: 678-683, 2001[Abstract/Free Full Text].

27.   Siragy, HM. Evidence that intrarenal bradykinin plays a role in regulation of renal function. Am J Physiol Endocrinol Metab 265: E648-E654, 1993[Abstract/Free Full Text].

28.   Tack, I, Marin-Castano E, Bascands JL, Pecher C, Ader JL, and Girolami JP. Cyclosporine A-induced increase in glomerular cyclic GMP in rats and the involvement of the endothelin B receptor. Br J Pharmacol 121: 433-440, 1997[Web of Science][Medline].

29.   Trabold, F, Pons S, Hagege AA, Bloch-Faure M, Alhenc-Gelas F, Giudicelli JF, Richer-Giudicelli C, and Meneton P. Cardiovascular phenotypes of kinin B2 receptor- and tissue kallikrein-deficient mice. Hypertension 40: 90-95, 2002[Abstract/Free Full Text].

30.   Wang, D, Yoshida H, Song Q, Chao L, and Chao J. Enhanced renal function in bradykinin B(2) receptor transgenic mice. Am J Physiol Renal Physiol 278: F484-F491, 2000[Abstract/Free Full Text].

31.   Yang, XP, Liu YH, Scicli GM, Webb CR, and Carretero OA. Role of kinins in the cardioprotective effect of preconditioning: study of myocardial ischemia/reperfusion injury in B2 kinin receptor knockout mice and kininogen-deficient rats. Hypertension 30: 735-740, 1997[Abstract/Free Full Text].

32.   Yang, XP, Liu YH, Mehta D, Cavasin MA, Shesely E, Xu J, Liu F, and Carretero OA. Diminished cardioprotective response to inhibition of angiotensin-converting enzyme and angiotensin II type 1 receptor in B(2) kinin receptor gene knockout mice. Circ Res 88: 1072-1079, 2001[Abstract/Free Full Text].


Am J Physiol Heart Circ Physiol 284(6):H1904-H1908
0363-6135/03 $5.00 Copyright © 2003 the American Physiological Society



This article has been cited by other articles:


Home page
Am. J. Physiol. Renal Physiol.Home page
M. Buleon, J. Allard, A. Jaafar, F. Praddaude, Z. Dickson, M.-T. Ranera, C. Pecher, J.-P. Girolami, and I. Tack
Pharmacological blockade of B2-kinin receptor reduces renal protective effect of angiotensin-converting enzyme inhibition in db/db mice model
Am J Physiol Renal Physiol, May 1, 2008; 294(5): F1249 - F1256.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
J. Allard, M. Buleon, E. Cellier, I. Renaud, C. Pecher, F. Praddaude, M. Conti, I. Tack, and J.-P. Girolami
ACE inhibitor reduces growth factor receptor expression and signaling but also albuminuria through B2-kinin glomerular receptor activation in diabetic rats
Am J Physiol Renal Physiol, October 1, 2007; 293(4): F1083 - F1092.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
C. Cayla, M. Todiras, R. Iliescu, V. V. Saul, V. Gross, B. Pilz, G. Chai, V. F. Merino, J. B. Pesquero, O. C. Baltatu, et al.
Mice deficient for both kinin receptors are normotensive and protected from endotoxin-induced hypotension
FASEB J, June 1, 2007; 21(8): 1689 - 1698.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
R. A. Skidgel, F. Alhenc-Gelas, and W. B. Campbell
Regulation of Cardiovascular Signaling by Kinins and Products of Similar Converting Enzyme Systems: Prologue: Kinins and related systems. New life for old discoveries
Am J Physiol Heart Circ Physiol, June 1, 2003; 284(6): H1886 - H1891.
[Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
284/6/H1904    most recent
01150.2002v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (13)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schanstra, J. P.
Right arrow Articles by Bascands, J.-L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schanstra, J. P.
Right arrow Articles by Bascands, J.-L.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2003 by the American Physiological Society.